Daniel Clayburgh1, Will Stott1, Rachel Bolognone1, Andrew Palmer1, Virginie Achim1, Scott Troob2, Ryan Li1, Daniel Brickman3, Donna Graville1, Peter Andersen1, Neil D Gross4. 1. Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University, Portland, Oregon. 2. Department of Otolaryngology-Head and Neck Surgery, Columbia University Medical Center, New York, New York. 3. Levine Cancer Institute, Carolinas Health System, Charlotte, North Carolina. 4. Department of Otolaryngology-Head and Neck Surgery, MD Anderson Cancer Center, Houston, Texas, U.S.A.
Abstract
OBJECTIVE: To determine if an extended perioperative course of corticosteroids will improve pain control following transoral robotic surgery (TORS). STUDY DESIGN: Randomized, double-blind, placebo-controlled trial. METHODS:Patients undergoing TORS for initial treatment of oropharyngeal squamous cell carcinoma received a single intraoperative dose of 10-mg dexamethasone and then were randomized to receive 8-mg dexamethasone every 8 hours, or placebo, for up to 4 days after surgery. Pain, measured by visual analog scale (VAS), was the primary outcome measure. Secondary outcome measures included length of stay, dysphagia assessments, and complications. RESULTS:VAS pain scores were similar between steroid and placebo cohorts on postoperative day (POD) 1, 2, and 7 through 21, although they significantly improved in the steroid cohort on POD 3. The steroid cohort also demonstrated a decreased hospital length of stay (median 1 day) and improvement in diet consistency, as measured by the performance status scale on POD 7 through 21. There was no difference in complications between the steroid and placebo cohorts. CONCLUSION: Extended perioperative corticosteroids after TORS is safe and may allow earlier improvement in diet consistency and decreased length of hospital stay, although postoperative pain appears minimally affected. LEVEL OF EVIDENCE: 1b. Laryngoscope, 127:2558-2564, 2017.
RCT Entities:
OBJECTIVE: To determine if an extended perioperative course of corticosteroids will improve pain control following transoral robotic surgery (TORS). STUDY DESIGN: Randomized, double-blind, placebo-controlled trial. METHODS:Patients undergoing TORS for initial treatment of oropharyngeal squamous cell carcinoma received a single intraoperative dose of 10-mg dexamethasone and then were randomized to receive 8-mg dexamethasone every 8 hours, or placebo, for up to 4 days after surgery. Pain, measured by visual analog scale (VAS), was the primary outcome measure. Secondary outcome measures included length of stay, dysphagia assessments, and complications. RESULTS: VAS pain scores were similar between steroid and placebo cohorts on postoperative day (POD) 1, 2, and 7 through 21, although they significantly improved in the steroid cohort on POD 3. The steroid cohort also demonstrated a decreased hospital length of stay (median 1 day) and improvement in diet consistency, as measured by the performance status scale on POD 7 through 21. There was no difference in complications between the steroid and placebo cohorts. CONCLUSION: Extended perioperative corticosteroids after TORS is safe and may allow earlier improvement in diet consistency and decreased length of hospital stay, although postoperative pain appears minimally affected. LEVEL OF EVIDENCE: 1b. Laryngoscope, 127:2558-2564, 2017.
Authors: Andrew J Holcomb; Rachael Kammer; Allison Holman; Tessa Goldsmith; Vasu Divi; Heather M Starmer; Joseph Zenga; Ryan Li; Urjeet A Patel; Jeremy D Richmon Journal: J Robot Surg Date: 2022-08-07
Authors: Beatrice C Go; Cammille C Go; Kevin Chorath; Alvaro Moreira; Karthik Rajasekaran Journal: World J Otorhinolaryngol Head Neck Surg Date: 2022-05-09